Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Nathan H. Fowler"'
Autor:
Ashwath Gurumurthi, Collin K. Chin, Lei Feng, Nathan H. Fowler, Paolo Strati, Fredrick B. Hagemeister, Luis E. Fayad, Jason R. Westin, Chizobam Obi, Janine Arafat, Ranjit Nair, Raphael E. Steiner, Sattva S. Neelapu, Christopher R. Flowers, Loretta J. Nastoupil
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102747- (2024)
Summary: Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity and
Externí odkaz:
https://doaj.org/article/ce025c6f41e44776b07e12e8ef403353
Autor:
Sriram Balasubramanian, Brendan Hodkinson, Stephen J. Schuster, Nathan H. Fowler, Judith Trotman, Georg Hess, Bruce D. Cheson, Michael Schaffer, Steven Sun, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, Ajay K. Gopal
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 61-73 (2022)
Abstract Background The single‐arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This bi
Externí odkaz:
https://doaj.org/article/8e668f1ebce046fb90165c45e83463d9
Autor:
Man Chun John Ma, Saber Tadros, Alyssa Bouska, Tayla Heavican, Haopeng Yang, Qing Deng, Dalia Moore, Ariz Akhter, Keenan Hartert, Neeraj Jain, Jordan Showell, Sreejoyee Ghosh, Lesley Street, Marta Davidson, Christopher Carey, Joshua Tobin, Deepak Perumal, Julie M. Vose, Matthew A. Lunning, Aliyah R. Sohani, Benjamin J. Chen, Shannon Buckley, Loretta J. Nastoupil, R. Eric Davis, Jason R. Westin, Nathan H. Fowler, Samir Parekh, Maher Gandhi, Sattva Neelapu, Douglas Stewart, Kapil Bhalla, Javeed Iqbal, Timothy Greiner, Scott J. Rodig, Adnan Mansoor, Michael R. Green
Publikováno v:
Haematologica, Vol 107, Iss 3 (2021)
B-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with unique molecular etiologies. Common subtypes of B-NHL, such as diffuse large B-cell lymphoma, have been comprehensively interr
Externí odkaz:
https://doaj.org/article/fc029b784cbf42fa99be555459101032
Autor:
Martin Dreyling, Michael Dickinson, Joaquin Martinez Lopez, Arne Kolstad, Jason P Butler, Monalisa Ghosh, Leslie L. Popplewell, Julio Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, Phoebe Joy Ho, Jose A. Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J M Ferreri, Takanori Teshima, Piers E.M. Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Ines Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O'Donovan, Roberto Ramos, Aisha Masood, Catherine Thieblemont, Nathan H. Fowler, Stephen J. Schuster
Publikováno v:
Blood. 140:1459-1463
Autor:
Paolo Strati, Ankur Varma, Sherry Adkins, Loretta J. Nastoupil, Jason Westin, Fredrick B. Hagemeister, Nathan H. Fowler, Hun J. Lee, Luis E. Fayad, Felipe Samaniego, Sairah Ahmed, Yiming Chen, Sandra Horowitz, Sara Arafat, Swapna Johncy, Partow Kebriaei, Victor Eduardo Mulanovich, Ella Ariza Heredia, Sattva S. Neelapu
Publikováno v:
Haematologica, Vol 106, Iss 10 (2020)
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients with relapsed or refractory la
Externí odkaz:
https://doaj.org/article/58088487f8c942138e28d376e4588649
Autor:
Paolo Strati, Mohamed Amin Ahmed, Nathan H. Fowler, Loretta J. Nastoupil, Felipe Samaniego, Luis E. Fayad, Fredrick B. Hagemeister, Jorge E. Romaguera, Alma Rodriguez, Michael Wang, Jason R. Westin, Chan Cheah, Mansoor Noorani, Lei Feng, Richard E. Davis, Sattva S. Neelapu
Publikováno v:
Haematologica, Vol 105, Iss 7 (2020)
The impact of pre-treatment maximum standardized uptake value (SUVmax) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not been explored. We performed a retrospective analysis of 346 patients with advanced stage f
Externí odkaz:
https://doaj.org/article/23a6b31510304286b70debb032dfe22e
Autor:
Hua-Jay J. Cherng, Ryan Sun, Bryant Sugg, Russell Irwin, Haopeng Yang, Cao Cuong Le, Qing Deng, Luis Fayad, Nathan H. Fowler, Simrit Parmar, Raphael Steiner, Fredrick Hagemeister, Ranjit Nair, Hun Ju Lee, Maria Rodriguez, Felipe Samaniego, Swaminathan P. Iyer, Christopher R. Flowers, Linghua Wang, Loretta J. Nastoupil, Sattva S. Neelapu, Sairah Ahmed, Paolo Strati, Michael R. Green, Jason Westin
Publikováno v:
Blood. 140:504-515
Patients with relapsed or refractory large B-cell lymphomas (rrLBCL) can achieve long-term remission after CD19 chimeric antigen receptor T-cell therapy (CART19). However, more than half of recipients will experience treatment failure. Thus, approach
Autor:
Guangchun Han, Qing Deng, Mario L. Marques-Piubelli, Enyu Dai, Minghao Dang, Man Chun John Ma, Xubin Li, Haopeng Yang, Jared Henderson, Olga Kudryashova, Mark Meerson, Sergey Isaev, Nikita Kotlov, Krystle J. Nomie, Alexander Bagaev, Edwin R. Parra, Luisa M. Solis Soto, Simrit Parmar, Fredrick B. Hagemeister, Sairah Ahmed, Swaminathan P. Iyer, Felipe Samaniego, Raphael Steiner, Luis Fayad, Hun Lee, Nathan H. Fowler, Christopher R. Flowers, Paolo Strati, Jason R. Westin, Sattva S. Neelapu, Loretta J. Nastoupil, Francisco Vega, Linghua Wang, Michael R. Green
Publikováno v:
Blood Cancer Discov
Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse tumor and immune cell populations of FL and identified
Autor:
Grzegorz S. Nowakowski, Mark Winderlich, Sumeet Ambarkhane, Günter Fingerle-Rowson, Debarshi Dey, Stephan Parche, Sascha Tillmanns, Nuwan C. Kurukulasuriya, Bruce Feinberg, Gilles Salles, Nathan H. Fowler, Erika Meli, Claudia Castellino, Anna Maria Barbui, Maurizio Frezzato, Dario Marino, Thomas Rodgers, Pier Luigi Zinzani
Supplementary Methods, Tables, and Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd5b909d20f5f86c1b0721fbf284605
https://doi.org/10.1158/1078-0432.23183827
https://doi.org/10.1158/1078-0432.23183827
Autor:
Grzegorz S. Nowakowski, Mark Winderlich, Sumeet Ambarkhane, Günter Fingerle-Rowson, Debarshi Dey, Stephan Parche, Sascha Tillmanns, Nuwan C. Kurukulasuriya, Bruce Feinberg, Gilles Salles, Nathan H. Fowler, Erika Meli, Claudia Castellino, Anna Maria Barbui, Maurizio Frezzato, Dario Marino, Thomas Rodgers, Pier Luigi Zinzani
Purpose:Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, in combination with lenalidomide, demonstrated efficacy in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), in the sing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a29b8d138b8ff55969aafd4e29ede446
https://doi.org/10.1158/1078-0432.c.6664573.v1
https://doi.org/10.1158/1078-0432.c.6664573.v1